Concord Medical Services Partners with CorestemChemon and ATG Lifetech to Innovate Drug Testing
- CorestemChemon partners with ATG Lifetech to enhance preclinical drug testing through advanced organoid and transcriptome technologies.
- The alliance aims to improve drug efficacy predictions and accelerate development timelines for pharmaceutical companies globally.
- CorestemChemon positions itself as a competitive global CRO, planning to launch new services by late 2025.
CorestemChemon and ATG Lifetech Forge Strategic Alliance to Enhance Preclinical Drug Testing
CorestemChemon, a leading GLP-certified preclinical contract research organization (CRO) in South Korea, has recently unveiled a strategic partnership with ATG Lifetech, a biotechnology firm recognized for its expertise in transcriptome analytics and organoid-based modeling. This collaboration is set to revolutionize preclinical testing processes for drug discovery, providing innovative solutions tailored for pharmaceutical and biotech companies across the U.S., Europe, and Asia. The partnership focuses on developing a transcriptome-based evaluation platform aimed at predicting drug efficacy and safety, alongside creating disease-relevant organoid models that will facilitate research in critical areas such as liver, heart, and blood-brain barrier studies.
The integration of ATG Lifetech’s advanced platforms into CorestemChemon’s offerings is anticipated to significantly enhance the scientific rigor of their preclinical services. Organoid-based assays, which have been shown to yield predictive accuracy five times greater than traditional 2D cell cultures, are at the forefront of this endeavor. By combining organoid technology with comprehensive whole-transcriptome analysis, the collaboration promises to enable earlier decision-making in drug development, effectively mitigating risks and accelerating timelines. This initiative aligns seamlessly with CorestemChemon's growth strategy centered around expanding high-margin, intellectual property-driven services, with the expectation of launching revenue-generating offerings by late 2025.
The partnership also signifies CorestemChemon's commitment to positioning itself as a competitive global CRO, capable of delivering services with superior biological relevance and regulatory readiness. CorestemChemon plans to showcase their joint research with ATG Lifetech at a major toxicology and preclinical science conference in Q4 2025, with aspirations for subsequent global service launches. This collaboration not only strengthens the companies’ market positions but also reflects a broader industry trend towards more sophisticated, data-driven approaches to preclinical testing, responding to the increasing demand for faster and more reliable drug development processes.
In related news, the Globee® Awards have opened submissions for their 13th Annual Globee® Awards for Leadership, which recognize outstanding achievements across various industries globally. This initiative aims to honor innovations that set new benchmarks in product and service excellence, inviting organizations to showcase their impactful accomplishments.
Additionally, the Managed Services Market is projected to see substantial growth, driven by the need for businesses to optimize IT operations and enhance cybersecurity amid a rapidly evolving technological landscape. This growth presents new opportunities for companies, including those in the healthcare sector, to leverage managed services for improved operational efficiency and cost savings.